From a clinical practice perspective, our findings suggest that for female T2DM patients, fasting glucagon levels might have the potential to serve as an auxiliary biomarker to help identify individuals at higher risk for coronary heart disease. Here, GCG is linked to type 2 diabetes mellitus.